Mark Dennis, PhDFellow at Denali Therapeutics
Building on 35 years of experience in protein and antibody engineering while a Principal Scientist at Genentech, Mark is currently a Fellow at Denali Therapeutics providing strategic direction and guidance for the development of protein therapeutics targeting neurological diseases. While at Genentech, Mark developed a practical method to deliver biotherapeutics across the blood-brain barrier, established that association with albumin could increase the serum half-life of biotherapeutics and was a key member of teams establishing early Antibody-drug conjugate (ADC) and T-cell Dependent
Bispecific (TDC) technologies for oncology. Mark has authored over 60 papers and contributed to over 30 granted patents.